The CBD Oil sector is filled with companies whose product lines are based around Full Spectrum CBD Oil, like Charlotte’s Web and CV Sciences, which contains 3 separate elements:
1) CBD
2) THC
3) Many other cannabinoids contained within hemp such as CBG, CBN, CBC, etc.
CANB is the only publicly traded company in America whose product line is instead based around THC-Free Pure CBD Isolate Oil, which contains only 1 ingredient:
1) CBD
I’m not sure whether the following two events are connected, but the timing sure seems coincidental:
On July 30th, the former commissioner of the FDA, Dr. Scott Gottlieb, published an editorial in the Washington Post strongly suggesting that the FDA is only ready to approve THC-Free Pure CBD Isolate Oil products in their framework due to be announced in late Sept/early Oct
On July 31st, CANB announced a private placement for $4M at .$.029, which is at zero discount to current market prices
It is very unusual to see this size of investment with no discount to current market prices, especially in an OTC stock
Here is why the FDA is going to create its framework around THC-Free Pure CBD Isolate Oil and why CANB is a monopoly stock perfectly positioned to explode when the FDA announces its framework:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.